Karl-Johan Myrén

A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome

Yan Wang, Karissa Johnston, Evan Popoff et al. · Journal of Medical Economics · 2020 · 33 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden

Nathaniel Henry, Jelena Jovanović, Max Schlueter et al. · Journal of Medical Economics · 2017 · 32 citations · Full text

Pharmacy, Hematology, Pharmacoeconomics +12

Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor <scp>VIII</scp> Fc fusion protein and conventional recombinant factor <scp>VIII</scp> products

Alfonso Iorio, Sangeeta Krishnan, Karl-Johan Myrén et al. · Haemophilia · 2017 · 31 citations

Medicine, Hematology, Pharmacotherapy +14

Long-Term Psychosocial and Health Economy Consequences of ADHD, Autism, and Reading-Writing Disorder

Agneta Nydén, Karl-Johan Myrén, Christopher Gillberg · Journal of Attention Disorders · 2007 · 30 citations

Education, Pediatrics, Special Education +17

Comparison of Lost Productivity Due to Eculizumab and Ravulizumab Treatments for Paroxysmal Nocturnal Hemoglobinuria in France, Germany, Italy, Russia, Spain, the United Kingdom, and the United States

Adrian R. Levy, Laura Dysart, Yogesh Patel et al. · Blood · 2019 · 13 citations

Medicine, Hematology, Pharmacotherapy +8